Our programs target rapidly accelerated fibrosarcoma/ mitogen‑activated protein kinase (RAF/MEK) and focal adhesion kinase (FAK). Preclinical research has shown that these targets are important for both cancer cell survival and the tumor microenvironment that supports the cancer cells.